FDA approves Apellis' retinal disease drug as competitor expects August decision

Kyle LaHucik

Senior Reporter

The FDA approved Apellis Pharmaceuticals’ drug for geographic atrophy secondary to age-related macular degeneration after pushing back the green light decision by three months …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves Apellis' retinal disease drug as competitor expects August decision

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

At least seven drugmakers say they will participate in round two of IRA negotiations

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Bipartisan 'pill penalty' fix and other bills vie for inclusion in reconciliation package

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

How AI can address ongoing challenges in the life sciences industry

FDA ap­proves Apel­lis' reti­nal dis­ease drug as com­peti­tor ex­pects Au­gust de­ci­sion

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA approves Apellis' retinal disease drug as competitor expects August decision